USFDA classifies inspection of Lupin's Pithampur facility as OAI

24 Apr 2019 Evaluate

The United States Food and Drug Administration (USFDA) has classified the inspection conducted at Lupin's Pithampur (Indore) Unit-2 facility in January 2019 as Official Action Indicated (OAI). The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

The company does not believe that this classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2111.95 22.30 (1.07%)
17-Dec-2025 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.00
Dr. Reddys Lab 1272.55
Cipla 1496.30
Zydus Lifesciences 917.95
Lupin 2111.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×